Lunch & Learn with GlaxoSmithKline's (GSK) Jon Collins

When: 
Wednesday, April 19, 2017 - 11:45am to 12:45pm
Location: 
Medical Center North, Room C2209
Topic: 
A prescription for success: academic-industry collaborations

 

Please join us Wednesday, April 19th from 11:45am to 12:45pm at Medical Center North C2209 for a lunch and learn hosted by the Vanderbilt School of Medicine in partnership with CTTC.

 

Come hear Dr. Jon Collins, Director of Chemistry for GlaxoSmithKline’s (GSK) Discovery Partnerships with Academia program.  Jon will discuss the importance of academic-industry collaborations in the biological and pharmaceutical fields, and will describe GSK’s program for academic partnerships – known as DPAc.  To conclude the lecture, Jon will announce a Vanderbilt-specific Request for Proposals, whereby Vanderbilt scientists can apply to receive up to $150k in support of their early stage small molecule research efforts. 

Additional information about the DPAc program can be found at the following link: http://www.dpac.gsk.com/.

The event is open to all members of the Vanderbilt community. Registration is required, as seating is limited. Lunch will be provided.

 

About the speaker:

Jon Collins
Director, US DPAc Chemistry

Jon Collins received his PhD in organic chemistry from Indiana University.  After completing a postdoctoral fellowship at Harvard University, he joined GSK in 1995 and has since led successful drug discovery research teams that span novel therapeutic target selection, hit identification/optimization in multiple target classes, and lead optimization to candidate selection in cardiovascular, metabolic, and inflammatory diseases.

He has served as co-author on more than 80 publications in peer-reviewed scientific journals and is a named inventor on 16 patents and patent applications.

Jon has collaborated extensively with the academic community throughout his scientific career and joined the Discovery Partnership with Academia (DPAc) team in 2011 in order to establish and lead joint academic-GSK drug discovery collaborations across North America.